[Clinical estimation of 1-alpha-hydroxycholecalciferol in treatment of patients with chronic renal failure].
31 adult patients (15 male and 16 female) with chronic renal failure were treated for 6 months with 1-alfa-hydroxycholecalciferol on a dose 0.25-2.0 micrograms/24 h. 15 patients with not very advanced renal failure (serum creatinine level 176.8-442 mumol/l) received conservative therapy (group I), 16 patients with serum creatinine value 884-1326 mumol/l were treated by intermittent hemodialysis (group II). The statistically significant decrease of serum alkaline phosphatase activity in group I and II (p < 0.01), the rise of serum calcium level in group I (p < 0.005) were determined. Half of the patients from both the groups stated the relief or disappearance of bone and joint pains and muscle weakness. Besides in group I significant decrease of creatinine clearance (p < 0.001) and increase of serum urea and creatinine value (p < 0.01) were noticed. On the basis of these results we can conclude that the treatment with 1-alfa-hydroxycholecalciferol, produced by "Polfa", ought to be introduced gradually with increasing doses and frequent monitoring of calcium-phosphate metabolism and renal function parameters.
Chodorowski
Z
Z
Kliniki Chorób Nerek I.Ch.W. AM, Gdańsku.
Rutkowski
B
B
Wielgosz
A
A
Chamienia
A
A
Sulima-Gillow
A
A
Manitius
A
A
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D014508:Urea / Q000097:blood
D006887:Hydroxycholecalciferols; D014508:Urea; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium; C008088:alfacalcidol
Ocena kliniczna 1-alfa-hydroksycholekalcyferolu w leczeniu chorych na przewlekła niewydolność nerek.